Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study (Q36081779)

12 August 2017

Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study (English)

1 reference

12 August 2017

1 reference

G Facendola

1

1 reference

12 August 2017

M C Locatelli

2

1 reference

12 August 2017

G Pizzocaro

3

1 reference

12 August 2017

L Piva

4

1 reference

12 August 2017

C Pegoraro

5

1 reference

12 August 2017

E B Pallavicini

6

1 reference

12 August 2017

A Signaroldi

7

1 reference

12 August 2017

M Meregalli

8

1 reference

12 August 2017

F Lombardi

9

1 reference

12 August 2017

G D Beretta

10

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 December 1995

1 reference

British Journal of Cancer

12 August 2017

1 reference

12 August 2017

72

1 reference

12 August 2017

6

1 reference

12 August 2017

1531-1535

1 reference

Interferon treatment of renal cell carcinoma. Current status and future prospects

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034091

Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034091

Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034091

Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034091

Reporting results of cancer treatment

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034091

Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034091

Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034091

Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034091

alpha-Interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patients

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034091

The natural history of metastatic renal cell carcinoma: a computer analysis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034091

Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034091

Optimal two-stage designs for phase II clinical trials

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034091

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2034091

Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma

11 July 2018

1 reference

12 December 2020

Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma

1 reference

12 December 2020

Further experience with recombinant interferon alfa-2a with vinblastine in metastatic renal cell carcinoma: a progress report

1 reference

12 December 2020

Renal cell carcinoma. Prognostic significance of morphologic parameters in 121 cases

1 reference

12 December 2020

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer

1 reference

12 December 2020

A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2a

1 reference

12 December 2020

A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1995.542

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

8519672

1 reference